Losartan metabolite EXP3179: an AT1-receptor-independent treatment strategy for patients with the metabolic syndrome?
Rossi
Gian Paolo
GP
D047228:Angiotensin II Type 1 Receptor Blockers / Q000378:metabolism* / Q000627:therapeutic use*; D052246:Cyclooxygenase 2 Inhibitors / Q000378:metabolism; D015237:Dinoprost / Q000378:metabolism; D006801:Humans; D018799:Intercellular Adhesion Molecule-1 / Q000378:metabolism; D019808:Losartan / Q000031:analogs & derivatives* / Q000378:metabolism* / Q000494:pharmacology / Q000627:therapeutic use*; D024821:Metabolic Syndrome / Q000188:drug therapy* / Q000378:metabolism*; D047495:PPAR gamma / Q000819:agonists / Q000378:metabolism; D044140:Receptor, Angiotensin, Type 1 / Q000378:metabolism*; D013928:Thromboxane A2 / Q000378:metabolism
D047228:Angiotensin II Type 1 Receptor Blockers; D052246:Cyclooxygenase 2 Inhibitors; D047495:PPAR gamma; D044140:Receptor, Angiotensin, Type 1; D018799:Intercellular Adhesion Molecule-1; C073600:2-butyl-4-chloro-1-((2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl)-1H-imidazole-5-carboxaldehyde; D013928:Thromboxane A2; D015237:Dinoprost; D019808:Losartan